Racial Disparities in the Utilization of Novel Agents for Frontline Treatment of Multiple Myeloma

Research output: Contribution to journalArticle

Abstract

We reviewed the utilization patterns of bortezomib and lenalidomide using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. Bortezomib utilization was 31% less likely for African Americans compared to whites. There was no statistically significant difference in lenalidomide utilization when other factors were controlled. We postulated that travel or logistical issues, structural barriers in the medical system, and preferences and biases among patients and providers may also be involved in the observed treatment disparities.

Original languageEnglish
JournalClinical Lymphoma, Myeloma and Leukemia
DOIs
StateAccepted/In press - Jan 1 2020

Keywords

  • Access barriers
  • Cancer disparities
  • Inequity
  • Race
  • SEER-Medicare

Fingerprint Dive into the research topics of 'Racial Disparities in the Utilization of Novel Agents for Frontline Treatment of Multiple Myeloma'. Together they form a unique fingerprint.

  • Cite this